(AQP5), a water channel, plays key roles in salivary secretion. The novel phosphorylation of AQP5 was investigated by using human salivary gland (HSG) cells and mouse salivary glands. In the HSG cells stably transfected with a wild-type mouse AQP5 construct, a protein band immunoreactive with antibody against phosphorylated PKA substrate was detected in the AQP5 immunoprecipitated sample, and its intensity was enhanced by short-term treatment of the cells with 8-bromocAMP, forskolin, or phorbol 12-myristate 13-acetate, but not by that with A23187 calcium ionophore. Such enhancement was inhibited in the presence of H-89, a PKA inhibitor. An AQP5 mutant (AQP5-T259A) expressed by transfection of HSG cells was not recognized by anti-phosphorylated PKA substrate antibody, even when the cells were stimulated with the protein kinase activators. Immunoblotting and immunofluorescence studies using a specific antibody detecting AQP5 phosphorylated at its Thr259 demonstrated that AQP5 was rapidly and transiently phosphorylated at the apical membrane of acinar cells in the submandibular and parotid glands after administration of isoproterenol, but not pilocarpine. Furthermore, both AQP5 and AQP5-T259A were constitutively localized at the plasma membrane in HSG cells under the resting and forskolin-stimulated conditions. These results suggest that AQP5 is phosphorylated at its Thr259 by PKA through cAMP, but not Ca 2ϩ , signaling pathways, and that this phosphorylation does not contribute to AQP5 trafficking in the salivary gland cells. submandibular gland; parotid gland; human salivary gland cell; protein kinase A THE PRIMARY SALIVA PRODUCTION by salivary gland acinar cells is principally regulated by both Ca 2ϩ and cAMP signaling pathways, the cells of which are activated by binding of neurotransmitters of the autonomic nervous systems to their respective receptors (23, 24) . In general, stimulation of the ␣-adrenergic or muscarinic type 3 acetylcholine receptor (M3R) evokes a copious fluid secretion through Ca 2ϩ signaling associated with inositol 1,4,5-trisphosphate (16, 19) . On the other hand, stimulation of ␤-adrenergic or vasoactive intestinal peptide receptors causes an exocytosis of proteins in secretory granules through cAMP signaling and hence elicits salivary protein secretion (23). These saliva secretions require water as a solvent to deliver salivary components into the oral cavity through the salivary gland ducts.
submandibular gland; parotid gland; human salivary gland cell; protein kinase A THE PRIMARY SALIVA PRODUCTION by salivary gland acinar cells is principally regulated by both Ca 2ϩ and cAMP signaling pathways, the cells of which are activated by binding of neurotransmitters of the autonomic nervous systems to their respective receptors (23, 24) . In general, stimulation of the ␣-adrenergic or muscarinic type 3 acetylcholine receptor (M3R) evokes a copious fluid secretion through Ca 2ϩ signaling associated with inositol 1,4,5-trisphosphate (16, 19) . On the other hand, stimulation of ␤-adrenergic or vasoactive intestinal peptide receptors causes an exocytosis of proteins in secretory granules through cAMP signaling and hence elicits salivary protein secretion (23) . These saliva secretions require water as a solvent to deliver salivary components into the oral cavity through the salivary gland ducts.
Water channel proteins, known as aquaporins (AQPs), facilitate the transport of water and small solutes across the cell membrane and play a variety of roles in physiological processes, including salivary secretion (28) . Among the 13 known isoforms in the mammalian AQP family (8) , AQP5 is a water-selective AQP and is primarily expressed in the lungs, trachea, cornea, and exocrine glands, such as lacrimal and major salivary glands, the latter of which include the submandibular gland (SMG), parotid gland (PG), and sublingual gland (28) . In the salivary glands, most of the AQP5 is localized at the luminal apical membrane, including intercellular canaliculi, of serous-type acinar cells (17, 22) , but some is detected on the basal membrane (18, 21) . Several groups reported that AQP5 is also expressed in the apical membrane of intercalated duct cells (5, 11) . The saliva volume of AQP5-knockout mice is decreased by Ͼ60% of that of normal mice when the muscarinic receptor in salivary glands is stimulated by pilocarpine, suggesting that AQP5 plays a critical role in the transcellular water secretion from the salivary gland acinar cells (15) .
Because the amino acid sequence of AQP5 is very close to that of AQP2 (7) , whose cAMP-dependent phosphorylation regulates its intracellular trafficking in the kidney collecting duct (1, 4) , many studies have been focused on the regulation of AQP5 in several types of epithelial cells, especially that of its membrane expression and intracellular trafficking through the Ca 2ϩ and cAMP signaling pathways. Biochemical analysis using rat PG slices has revealed that AQP5 in the apical membrane fraction is rapidly and transiently increased upon the stimulation of M3Rs, raising the possibility that AQP5 is translocated from some cytoplasmic compartment to the apical membrane (9, 10) . In human salivary gland (HSG) cells transfected with AQP5 cDNA, treatment with thapsigargin, an inhibitor of the Ca 2ϩ pump in the endoplasmic reticulum, causes AQP5 translocation from intracellular vesicles to the plasma membrane in association with an elevation of the intracellular Ca 2ϩ (27) . However, immunocytochemical analysis of rat salivary glands did not show any difference in AQP5 distribution at the apical membrane between resting and Ca 2ϩ -mobilized conditions (5) . In a mouse lung epithelial cell line, MLE-12 cells, short-term activation of the cAMP signaling pathway facilitates the internalization of endogenous AQP5 from the apical membrane and reduces cellular AQP5 levels, at least in part, by lysosomal degradation (26) . On the other hand, long-term activation of the same pathway increases AQP5 levels at the apical membrane (26, 36) . Recently, Woo and colleagues (34) reported that cAMP-dependent phosphorylation of AQP5 at its Ser156 may not be involved in the AQP5 membrane expression and trafficking in human bronchial epithelial cells. Instead, they described the possibility that AQP5 phosphorylation at this site may affect cell proliferation through the Ras signaling pathway (35) . In polarized MadinDarby canine kidney (MDCK) cells, AQP5 is localized at the apical membrane (32, 33) . In a previous publication (13) we have shown that upon cAMP-stimulation in MDCK cells, green fluorescent protein-tagged AQPS and its mutant at Thr259, which is a putative phosporylation site, were localized in intracellular vesicles and trafficked to the apical membrane. This suggested to us that phosporylation at Thr259 was not necessary for AQP5 trafficking, however, no direct experimental evidence of Thr259 phosporylation was provided.
Thus the behavior of AQP5, especially that in membrane trafficking, through the signaling pathways seems to depend on the cell type and the methods employed. Especially regulation of AQP5 expression through the cAMP signaling in the salivary gland cells, in which phosphorylation of this AQP is possibly involved, is poorly understood. In the present study, using a HSG cell line in vitro and mouse salivary glands in vivo, we examined whether AQP5 is phosphorylated under certain physiological conditions, and what is the entity of such phosphorylation, if any. As a result, we found that AQP5 was actually phosphorylated at its Thr259 through cAMP signaling. We investigated also the possibility of involvement of this phosphorylation in the intracellular trafficking of AQP5.
MATERIALS AND METHODS
Animals. Male Institute of Cancer Research (ICR; CD-1) mice, 8 wk of age (Japan SLC, Shizuoka, Japan), were maintained under a standard condition allowing free access to tap water and chow. All animal experiments were approved by The Animal Care and Use Committee of The University of Tokushima (no. 08066). Mice were intraperitoneally injected with (Ϫ)-isoproterenol hydrochloride (SigmaAldrich, St. Louis, MO; 6 mg/kg body wt and 0.2 ml/40 g body wt) or pilocarpine hydrochloride (Wako Pure Chemical, Osaka, Japan; 10 mg/kg body wt and 0.2 ml/40 g body wt) dissolved in physiological saline. The SMG and PG were removed at 5, 10, 30, 60, and 120 min after agonist or saline injections. The samples immediately removed after saline-injection were regarded as 0-min control. For immunoblot analysis, tissues were dissected, immediately frozen in liquid nitrogen, and stored at Ϫ80°C until examined. For immunohistochemistry, the tissues were directly embedded in Tissue-tek OCT compound (Sakura Finetek, Tokyo, Japan) and were immediately frozen in liquid nitrogen.
Preparation of the AQP5-enriched fraction and solubilization of AQP5. The mouse SMG and PG were homogenized with a glass mortar homogenizer fitted with a Teflon pestle (Wheaton Science Products, Millville, NJ) in an ice-cold homogenizing buffer [50 mM Tris·HCl (pH 8.0), 150 mM NaCl, 10 mM NaF, 1 mM Na 3VO4, and a complete proteinase inhibitor cocktail (Roche Diagnostics, Basel, Switzerland)], and centrifuged at 800 g for 10 min at 4°C to remove cell debris and nuclei. The supernatants were differentially centrifuged at 4°C, i.e., first at 17,000 g for 20 min, then at 105,000 g for 1 h. The resultant precipitates were resuspended in the same buffer. Protein concentrations were determined by use of Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA) with BSA as a standard.
For effective AQP5 solubilization, the AQP5-enriched fraction (17,000 g precipitate) of the SMG was simultaneously or sequentially treated with cholesterol-sequestering agents and other detergents, as follows: i.e., first, saponin (1%; MP Biomedicals, Solon, OH), methyl-␤-cyclodextrin (1%; Sigma-Aldrich), or digitonin (1%; Wako) to sequester cholesterol, and then with 3-[(3-cholamidopropyl)dimethylammonio]-propanesulfonate (CHAPS, 1%; Dojindo, Kumamoto, Japan), Triton X-100 (1%; Sigma-Aldrich), or octyl ␤-D-glucopyranoside (100 mM; Sigma-Aldrich). Each treatment was carried out for 30 min on ice. The AQP5-enriched fraction treated with 0.1% SDS (Wako) was regarded as the control for complete solubilization. The detergent-treated samples were separated again by centrifugation at 17,000 g and subjected to immunoprecipitation described below or directly to denaturation at 70°C for 10 min in SDS-PAGE sample buffer containing 5% 2-mercaptoethanol.
HSG cells transfected with mouse AQP5 constructs. Mouse AQP5 cDNA was cloned from the SMG of a male ICR (CD-1) mouse; i.e., AQP5 cDNA was synthesized by standard RT-PCR using the following set of primers: 5=-CTGCTAGCACCATGAAGAAGGAGGT-GTG-3= (forward primer) and 5=-GTGGATCCTCAGTGTGCCGT-CAGCTCGA-3= (reverse primer), which contained an NheI site and a BamHI site, respectively. The cDNA thus obtained was inserted into the pIRES-hygro mammalian expression vector (Clontech, Mountain View, CA). To link a sequence including the FLAG tag (MDYKD-DDDK) to the NH 2-terminus of mouse AQP5 (FLAGAQP5), we performed PCR using the AQP5 vector as a template, the forward primer 5=-CTAGCTAGCATGGATTACAAGGATGACGATGACA-AGATGAAGAAGGAGGT-3=, which contained an NheI site, and the reverse primer described above, and the resultant DNA fragment was then inserted into the same vector. For substitution of Ser or Thr as predicted phosphorylatable motifs in AQP5 with alanine (AQP5-S152A, -T155A, -S156A, and -T259A), site-directed mutagenesis was carried out by PCR, and the sequences of the DNA prepared were confirmed before using the DNA for transfection experiments.
HSG cells (gift from Mitsunobu Sato, The University of Tokushima) were transiently or stably transfected with the AQP5 vectors by using FuGENE HD (Roche Applied Science, Mannheim, Germany), according to manufacturer's instructions. To obtain cell clones stably expressing AQP5, we selected such cells by culturing them in medium containing hygromycin B (300 g/ml) without other antibiotics for at least 2 wk. The colonies were cloned and maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, and 300 g/ml hygromycin B.
Treatment of the HSG cells with protein kinase activator/inhibitor or calcium ionophore. The HSG cells transiently or stably expressing AQP5 were grown to confluence on culture dishes or on noncoated cover glasses. They were incubated with 50 M 8-bromo-cAMP (Sigma-Aldrich), 50 M forskolin (Sigma-Aldrich), 1 M phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich), or 10 M A23187 calcium ionophore (Sigma-Aldrich) in DMEM containing 10% FBS. In some experiments, the cells were pretreated for 30 min with H-89 (Sigma-Aldrich) and then subsequently treated with the protein kinase activators and H-89. After treatment with the activators, the cells were washed three times with ice-cold PBS containing 1 mM CaCl2 and 0.5 mM MgCl2 (PBS-CM).
Development of antibody against AQP5 phosphorylated at its Thr259. A phospho-peptide, CEERKKpTIELTA (referred to as pT259 peptide), and a nonphosphorylated peptide, CEERKKTIELTA (referred to as non-pT259 peptide), corresponding to the amino acid positions 254 -264 of mouse AQP5, were commercially synthesized. The pT259 peptide was conjugated to a mariculture keyhole limpet hemocyanin prelinked with maleimide (Pierce, Rockford, IL), and the complex was intradermally injected into a rabbit for immunization. Affinity purification of the anti-phosphorylated AQP5 antibody (antipAQP5 antibody) was carried out by a two-step purification protocol using Sulfolink gel (Pierce), coupled with pT259 or non-pT259 peptide. In brief, the rabbit serum was incubated with the non-pT259 peptide-coupled gel at 4°C overnight to remove antibodies that had reacted with the nonphosphorylated AQP5, and then the flow through fraction was recovered and incubated again with fresh gel coupled with the same peptide. This process was repeated three times. The serum thus treated was finally incubated with the pT259 peptidecoupled gel. The eluate obtained from the pT259 peptide-coupled gel by washing with 0.1 M glycine (pH 2.8) was neutralized and used as the anti-pAQP5 (T259) antibody. On the other hand, the antibody bound to non-pT259 peptide was also eluted and used in ELISA. The specificity of this antibody was confirmed by ELISA, as described previously (6) , immunoblotting, and immunohistochemistry.
Treatment with lambda protein phosphatase. AQP5-enriched fractions of the SMG and PG from mice at 5 min after isoproterenol injection were prepared in the homogenizing buffer depleted of the phosphatase inhibitors. Ten micrograms of the fractions were incubated with 100 units of lambda protein phosphatase (New England Biolaboratories, Ipswich, MA) and 1% Trition X-100 in a 10-l buffer supplied by the manufacturer for 60 min at 30°C. After incubation, the samples were denatured in SDS-sample buffer and subjected to immunoblotting, as described below.
Immunoprecipitation. Cultured HSG cells or the AQP5-enriched fractions of the mouse SMG or PG were incubated in homogenization buffer containing 1% saponin for 30 min on ice before incubation with 1% Triton X-100 (final concentration) for 30 min on ice. The supernatants containing solubilized AQP5 were obtained by centrifugation at 17,000 g for 20 min. AQP5 was immunoprecipitated from precleared supernatants by incubation with affinity-purified rabbit anti-AQP5 antibody (27) and protein A Sepharose CL-4B (GE Healthcare, Buckinghamshire, UK) overnight at 4°C. The gel was washed five times with the same buffer containing 1% saponin and 1% Triton X-100, followed by elution with SDS sample buffer containing 5% 2-mercaptethanol and 50 mM DTT. The proteins eluted were incubated at 95°C for 10 min. FLAG-tagged AQP5 was immunoprecipitated by using mouse anti-DYKDDDDK monoclonal antibody-linked agarose (Wako), washed, eluted with 0.1 M glycine-HCl (pH 2.8), and then denatured at 70°C in the SDS sample buffer. In most experiments, the eluate, after immunoprecipitation, was divided 9:1 by volume for detection of pAQP5 and AQP5, respectively.
Immunoblotting. The samples for immunoblotting of pAQP5 and AQP5 were prepared as described above, and the homogenate of the PG tissue was used as samples for amylase detection. The samples prepared were subjected to 10 or 12% polyacrylamide gel electrophoresis and then transferred onto an Immobilon-P polyvinylidene difluoride membrane (Millipore, Billerica, MA). After having been blocked with Block Ace (Dainippon Sumitomo Pharma, Osaka, Japan) or polyvinylidene difluoride blocking reagent (Toyobo, Osaka, Japan), the membrane was sequentially reacted with the following primary and secondary antibodies: goat anti-AQP5 antibody (0.1 g/ml; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit antiphospho-PKA (pPKA) substrate antibody (1:2,000; Cell Signaling Technology, Danvers, MA), rabbit anti-pAQP5 (T259) antibody (0.1 g/ml; this study), goat anti-amylase (0.2 g/ml; Santa Cruz Biotechnology), horseradish peroxidase (HRP)-conjugated rabbit anti-goat IgG (1:10,000; Beckman Coulter, Brea, CA), TrueBlot HRP-conjugated anti-rabbit IgG (1:20,000; eBioscience, San Diego, CA), or HRP-conjugated goat anti-rabbit IgG (1:10,000; Jackson Immunoreseach, Westgrove, PA). For the detection of proteins immunoreactive toward anti-pPKA substrate antibody and anti-pAQP5 (T259) antibody, both primary and secondary antibodies were diluted in Can Get Signal Immunoenhancer solutions (Toyobo). For the absorption test, pAQP5 (T259) antibody was preincubated with non-pT259 peptide or pT259 peptide at a concentration of 15 g/ml. Immunoreactions were finally visualized with enhanced chemiluminescence reagents (GE Healthcare), and the immunoblots were exposed to Fuji RX X-ray film (Fuji Film, Kanagawa, Japan).
Biotinylation assay of cell-surface proteins. HSG cells transfected with wild-type AQP5 cDNA (HSG AQP5-WT) were grown and treated with forskolin or vehicle (0.1% DMSO) for 5 min and then washed with ice-cold PBS-CM to remove forskolin and other proteins in the medium. Cell-surface proteins were biotinylated with a membrane-impermeable agent, EZ-link sulfo-NHS-LC-biotin (0.5 mg/ml; Pierce), in PBS-CM for 30 min on ice. Unreacted biotin was quenched by 50 mM NH4Cl in PBS-CM. After having been washed with PBS-CM, the cells were sequentially treated with saponin and Triton X-100, as described above, to solubilize the AQP5 effectively. The extracts obtained by solubilization were centrifuged, and the resultant supernatants were divided 3:1 by volume and used for collection of biotinylated proteins and AQP5 immunoprecipitation, respectively. Biotinylated proteins were bound to streptavidin agarose (Merck KGaA, Darmstadt, Germany), washed, and eluted with the SDS sample buffer. Each eluate was divided 9:1 by volume and used for the detection of pAQP5 and AQP5, respectively. After detection of AQP5 in biotinylated surface proteins by immunoblotting, the intensities of the band were calculated by using Image J software, and the data were statistically analyzed by performing Welch's t-test.
Immunofluorescence staining. Cryosections of freshly embedded tissues were mounted on matusnami adhesive silane-coated slides, fixed with methanol for 10 min at Ϫ20°C, and blocked with 3% BSA. Cultured cells grown on cover glasses were fixed with methanol for 20 min at Ϫ20°C, lightly permeabilized with 0.1% Triton X-100, and blocked with 3% BSA. For single immunofluorescence staining, the specimens were immunoreacted with rabbit anti-pAQP5 (T259) antibody (0.25 g/ml) that had been preincubated with non-pT259 peptide (15 g/ml) or with rabbit anti-AQP5 antibody (0.5 g/ml), followed by incubation with Alexa Fluor 488 labeled-donkey antirabbit IgG (1:500; Molecular Probes, Eugene, OR). For double immunofluorescence staining of pAQP5 and AQP5, the specimens were sequentially reacted with rabbit anti-pAQP5 (T259) antibody that had been preincubated with non-pT259 peptide, goat anti-AQP5 antibody (Santa Cruz; 1:500), and a mixture of Alexa Fluor 594 labeled-donkey anti-rabbit IgG (1:500; Molecular Probes) and Alexa Fluor 488 labeled-donkey anti-goat IgG (1:500; Molecular Probes). For the absorption test, anti-pAQP5 (T259) antibody was preincubated with non-pT259 peptide or pT259 peptide at a concentration of 15 g/ml. The specimens were examined under a confocal laser-scanning microscope (C1si-Ready; Nikon Instruments, Tokyo, Japan).
RESULTS

Characterization and solubilization of AQP5-enriched fraction.
We performed differential centrifugation to obtain an AQP5-enriched fraction from mouse salivary glands. Most of the AQP5 in the SMG and PG was recovered in the precipitate obtained at a 17,000 g low-speed centrifugation, whereas it was scarcely recovered in the precipitate obtained after 105,000 g high-speed centrifugation after the low-speed centrifugation (Fig. 1A) .
Subsequently, we examined the solubility of AQP5 in the 17,000 g precipitate, i.e., the AQP5-enriched fraction, to several detergent solutions, because the AQP5 protein could not be immunoprecipitated successfully by using a 0.1% SDSlysed fraction (data not shown). Previously, in the rat PG obtained in the unstimulated condition, it is reported that the majority of AQP5 exists in lipid rafts, which are resistant to nonionic detergents at lower temperatures (11) . To solubilize AQP5 effectively, we pretreated the AQP5-enriched fraction with saponin, methyl-␤-cyclodextrin, or digitonin on ice, which reagents are known as cholesterol-sequestering agents. The pretreated samples were next extracted with amphionic (CHAPS) or nonionic (Triton X-100 and octyl ␤-D-glucopyranoside) detergents. Figure 1B shows an AQP5 immunoblot of the 17,000 g supernatants and precipitates after solubilization of the AQP5-enriched fraction with the above reagents. AQP5 was slightly detected in the supernatant treated with Triton X-100, but not with CHAPS or octyl ␤-D-glucopyranoside when the AQP5-enriched fraction was not pretreated with cholesterol-sequestering agents. Neither methyl-␤-cyclodextrin nor digitonin had much effect on AQP5 solubilization, even if nonionic or amphionic detergents were added. On the other hand, saponin pretreatment before the addition of CHAPS or Triton X-100 solubilized AQP5 most effectively (Fig. 1B) . Simultaneous treatment with any of the cholesterolsequestering agents and nonionic detergent did not solubilize AQP5 effectively (data not shown). Therefore, we applied sequential treatment with saponin and Triton X-100 for preparation of the solubilized sample for AQP5 immunoprecipitation from mouse tissues and HSG cells.
Induction of phosphorylation of AQP5 in HSG cells. In this study, we used the HSG cell line, which was originally established from a human SMG carcinoma and displays a ductlike property (20) without endogenous human AQP5 expression (27) . To confirm phosphorylation of AQP5 in the HSG cells, we generated HSG cells stably transfected with wild-type mouse AQP5 (HSG AQP5-WT) or with FLAG-tagged wildtype mouse AQP5 (HSG FLAGAQP5-WT). Using solubilized samples obtained from both transfectants, we performed immunoprecipitation with rabbit anti-AQP5, followed by immunoblotting with anti-pPKA substrate antibody, which recognizes the PKA targeting sequence containing phosphorylated Ser or Thr (RR/KXpS/pT). In the unstimulated HSG AQP5-WT cells, a 28.3-kDa protein band immunoreactive with anti-pPKA substrate antibody was detected, and the intensity of this band was enhanced by treatment (10 min) with 50 M forskolin or 1 M PMA, an activator of adenylate cyclases or of conventional and novel PKC, respectively, but was slightly decreased by treatment with 10 M A23187, a calcium ionophore ( Fig. 2A, top) . The band was not detected in the forskolin-treated cell extract immunoprecipitated by normal rabbit IgG or in the buffer without the cell extract immunoprecipitated with anti-AQP5 antibody. In subsequent immunoblotting using the same membrane and anti-AQP5 antibody, the AQP5 band was detected at 27.0 kDa, which size was slightly smaller than that of the protein band immunoreactive with the anti-pPKA substrate antibody ( Fig.  2A, bottom) . After immunoprecipitation with anti-AQP5 antibody from the HSG FLAGAQP5-WT cells, the band immunoreactive with the anti-pPKA substrate antibody that appeared was 1.0 kDa larger than that obtained from the AQP5-WT cells because of the increase in molecular mass due to the FLAG tag connected to AQP5-WT, indicating that the band immunoreactive with anti-pPKA substrate antibody was derived from the AQP5 itself, but not from other proteins (Fig. 2B) . These results suggest that AQP5 was phosphorylated at a PKA- The submandibular gland (SMG) and parotid gland (PG) homogenates were differentially centrifuged at 17,000 g and then at 105,000 g. AQP5 in precipitates (prec) and supernatants (sup) obtained at each centrifugation speed were subjected to IB. B: effect of various detergents on solubilization of AQP5. The precipitate obtained by centrifugation of the SMG homogenate at 17,000 g was pretreated with either 1% saponin, 1% methyl-␤-cyclodextrin (M␤CD), or 1% digitonin before extraction with 1% CHAPS (C), 1% Triton X-100 (T), or 100 mM octyl ␤-D-glucopyranoside (OG) on ice. N, nontreatment with the amphionic or nonionic detergents. A sample treated with 0.1% SDS was used as a control indicating 100% solubilization. After treatment with the detergents, the samples were centrifuged again at the same speed to separate the supernatants and precipitates, which were then applied for AQP5 IB. targeted site(s) as one of PKA substrates in HSG cells, and that such phosphorylation could be induced by cAMP or PKC signaling.
As shown in Fig. 2B , the intensity of the band immunoreactive with the anti-pPKA substrate antibody in HSG FLA-GAQP5-WT cells was also slightly increased on treatment with forskolin or PMA, although its enhancement was not so prominent as that seen in the band in HSG AQP5-WT cells. The NH 2 -terminal tag of AQP5 may have interfered with access of the kinase(s) to the target site or may have interrupted the enzyme activity.
Identification of phosphorylation site in AQP5 and the related kinase. AQP5 has one consensus PKC target motif, SRR, at residues 152-154 in cytoplasmic loop D, and two consensus PKA/PKG target motifs, RRTS at 153-156 and RKKT at 256 -259, in the loop D and the C-tail domain, respectively. As described above, according to the information provided by the manufacturer, the anti-pPKA substrate antibody used in the present study can react with RR/KXpS/pT sequence. Therefore, this motif-specific antibody can recognize AQP5, if, at least, either Ser156 or Thr259 of this molecule is phosphorylated. To identify the phosphorylation site(s) in the AQP5 molecule, we performed an experiment to detect phosphorylated AQP5 (referred to as pAQP5) by the method described above in the HSG cells transiently transfected with wild-type and mutant AQP5 constructs (i.e., AQP5-WT, -S152A, -T155A, -S156A, and -T259A). In the HSG AQP5-WT, -S152A, -T155A, and -S156A cells, the band indicating pAQP5 was detected under the untreated condition, all of which intensities were enhanced by the treatment with 8-bromo-cAMP, forskolin, or PMA for 10 min (Fig. 3A) . On the other hand, in HSG AQP5-T259A cells, the band indicating pAQP5 did not appear, even when the cells were treated with the protein kinase activators, even though an adequate amount of AQP5-T259A had been immunoprecipitated (Fig. 3A) . Lack of the band detection by anti-pPKA substrate antibody in AQP5-T259A mutant suggests that Thr259 of AQP5 is a phosphorylation site.
However, there still remained the possibility that this particular AQP5 mutant, AQP5-T259A, might not have been immunoprecipitated completely/successfully by the anti-AQP5 antibody, since this antibody recognizes the AQP5 COOHterminal sequence where the T259A mutation was introduced. To exclude such a possibility, we prepared HSG cells transiently transfected with FLAG-tagged AQP5 constructs (i.e., FLAGAQP5-WT, -S152A, -T155A, -S156A, and -T259A), and performed the immunoprecipitation by using anti-FLAG antibody, followed by immunoblotting by anti-pPKA antibody. Similar to the result obtained from the nontagged mutant AQP5 experiments, the band indicating FLA-GAQP5-T259A phosphorylation was not detected after forskolin treatment (Fig. 3B) . These results again suggest that AQP5 at its Thr259 is a phosphorylation site that can be phosphorylated in the downstream signaling pathway of cAMP or PKC.
In the AQP5 molecule, Thr259 is a phosphorylation site located within a consensus sequence of the PKA target motif, but not within that of the PKC one. However, we found that treatment with PMA, a PKC activator, also strongly phosphorylated AQP5 at its Thr259. For further confirmation of the involvement of PKA, therefore, we examined the effect of H-89, a specific PKA inhibitor, on AQP5 phosphorylation in the HSGAQP5-WT cells (Fig. 3C ). H-89 pretreatment for 30 min dose-dependently decreased the intensity of the protein band immunoreactive with the anti-pPKA substrate antibody in the cells stimulated with 8-bromo-cAMP, forskolin, or PMA for 10 min, suggesting that PKA was involved in the phosphorylation of AQP5 at its Thr259. PMA would supposedly have activated PKA either directly or indirectly.
Development of anti-pAQP5 (T259) antibody. We developed an anti-peptide antibody against an AQP5 COOH-terminal domain, including phosphorylated Thr259. We first obtained serum from a rabbit immunized with the conjugate of pT259 peptide and keyhole limpet hemocyanin and purified it by A: analysis of AQP5 phosphorylation site by site-directed mutagenesis using HSG cells transiently expressing various AQP5 mutants (AQP5-WT, -S152A, -T155A, -S156A, and -T259A). The cells transfected with the AQP5 constructs or without plasmid (Ϫ) were treated with 8-bromo-cAMP (cAMP), 50 M FK, 1 M PMA, or vehicle for 10 min. After IP with anti-AQP5 Ab, the samples were immunoblotted with anti-pPKA substrate Ab (pPKA sub) and anti-AQP5 Ab (AQP5). B: analysis of AQP5 phosphorylation site using HSG cells transiently expressing various FLAG-tagged AQP5 mutants (FLAGAQP5-WT, -S152A, -T155A, -S156A, and -T259A). The cells treated with FK were subjected to IP using anti-FLAG Ab followed by IB. The immunoprecipitated sample with use of anti-AQP5 Ab from FK-treated HSG AQP5-WT cells was used as the positive control, and the sample from nontransfected HSG cells (Ϫ) was used as the negative control. C: effect of H-89, a PKA inhibitor, on the phosphorylation of AQP5. HSGAQP5-WT cells were pretreated with H-89 (0, 1, or 10 M) for 30 min and then treated for 10 min with the protein kinase activators and H-89. After IP with anti-AQP5 Ab, the samples were subjected to IB using anti-pPKA substrate Ab and anti-AQP5 Ab. using gels coupled with non-pT259 peptide or pT259 peptide. As shown in Fig. 4 , the ELISA data indicated that the antibody purified by using the non-pT259 peptide-coupled gel reacted with both pT259 peptide and non-pT259 peptide. In contrast, the final product (the fraction eluted from the pT259 peptidecoupled gel after passing the non-pT259 peptide gel), i.e., anti-pAQP5 (T259) antibody, reacted with pT259 peptide but not with the non-pT259 peptide, indicating that the antipAQP5 (T259) antibody thus purified specifically reacted with AQP5 phosphorylated at its Thr259. Further characterization of this antibody was performed as described in later sections.
Induction of phosphorylated AQP5 in vivo. We next examined the phosphorylation of AQP5 in the salivary glands of mice injected intraperitoneally with isoproterenol to activate cAMP signaling. Isoproterenol is a ␤-adrenergic agonist known also as a secretagogue of protein-rich saliva from the salivary glands. To detect pAQP5 by biochemical analysis, we employed the anti-pAQP5 (T259) antibody described above, in addition to the anti-pPKA substrate antibody. In the AQP5-immunoprecipitated samples of the SMG, pAQP5 bands were detected at the same electrophoretic position (28.3 kDa) and with a similar time course when either anti-pAQP5 (T259) antibody or anti-pPKA substrate antibody was used; both bands transiently increased in intensity, reaching a peak level at 5-10 min after isoproterenol injection, and then gradually decreased (Fig. 5A, left top) . A faint band was detected by the anti-pAQP5 (T259) antibody at a position lower than that of the main band. Regardless of phosphorylation, no remarkable difference was detected in the amount of AQP5 immunoprecipitated (Fig. 5A, left top) . By the direct immunoblotting (immunoblotting without immunoprecipitation) using antipAQP5 (T259) antibody and the same SMG samples, a similar time course pattern of changes in the pAQP5 band was observed (Fig. 5A, left bottom) . In contrast to isoproterenol injection, saline injection did not affect the band intensities in detection by anti-pAQP5 (T259) antibody or by anti-pPKA substrate antibody (Fig. 5A, right) . These results were confirmed by using samples from another set of mice following the direct immunoblotting (Fig. 5B) . In this second group of mice injected with isoproterenol or saline, the PG as well as SMG was examined. Isoproterenol injection transiently increased the band intensity of pAQP5 in the SMG and PG (Fig. 5B, left) , whereas saline injection did not (Fig. 5B, right) . Besides, an appreciable decrease in amylase content in the PG tissue was Fig. 4 . Reactivity of anti-pAQP5 (T259) Ab with phosphorylated and nonphosphorylated antigen peptide in ELISA. Anti-pAQP5 (T259) Ab was tested for its reactivity toward pT259 peptide and non-pT259 peptide. Circles, binding to pT259 peptide; triangles, binding to non-pT259 peptide; open symbols, Ab purified by the non-pT259 peptide gel; solid symbols, Ab purified by the pT259 peptide gel after passage through non-pT259 peptide gel, i.e., anti-pAQP5 (T259) Ab. A490 nm, absorbance at 490 nm. Ab. Change in amylase amount in the PG homogenates was shown as a positive control to confirm that Iso was effective to provoke amylase secretion. C: absorption test of anti-pAQP5 (T259) Ab. Anti-pAQP5 (T259) Ab was used for the direct IB before and after incubation with the peptides (pT259 or non-pT259) to detect pAQP5 in the SMG and PG from mice injected with Iso (5 min). D: reactivity of anti-pAQP5 (T259) Ab to phosphatase-treated sample. AQP5-enriched fractions of the SMG and PG obtained at 5 min after Iso injection were treated with or without lambda protein phosphatase. Direct IB of anti-pAQP5 (T259) Ab or anti-AQP5 Ab was performed. E: phosphorylation of AQP5 after pilocarpine (Pilo) injection. The AQP5-enriched fractions of the SMG and PG after Pilo injection were subjected to direct IB by using anti-pAQP5 (T259) Ab or anti-AQP5 Ab. AQP5-enriched fractions of tissue samples obtained at 5 min after Iso injection were used as positive controls.
observed after 30 min, suggesting that isoproterenol was effective on amylase secretion under the experimental condition employed here, although the initiation time of the secretion was not determined (Fig. 5B, left) .
To evaluate the specificity of the anti-pAQP5 (T259) antibody, we performed an absorption test on this antibody by direct immunoblotting (Fig. 5C ) and an experiment of protein phosphatase treatment (Fig. 5D ). For these immunoblotting experiments, we used the AQP5-enriched fractions prepared from the mouse salivary glands isolated at 5 min after isoproterenol injection. In the absorption test, the band for pAQP5 in both SMG and PG was clearly detected by the anti-pAQP5 (T259) antibody (Fig. 5C, left blot) and by the same antibody preincubated with the non-pT259 peptide (Fig. 5C, right blot) . However, the band was almost completely absent when the antibody that had been preincubated with pT259 peptide was used (Fig. 5C, center blot) . The faint band that appeared immediately below the main band (Fig. 5C, left blot) by this antibody was completely eliminated by preincubation with the non-pT259 peptide (Fig. 5C, right blot) . In the experiment of protein phosphatase treatment, the immunoblot band for pAQP5 in the SMG and PG was completely eliminated by pretreatment with lambda protein phosphatase (Fig. 5D, top  blot) . In addition, in detection by anti-AQP5 antibody, the minor band, the size of which was a little bit bigger than the major band of AQP5 and shown especially in the PG sample, was eliminated by pretreatment with the phosphatase (Fig. 5D , bottom blot), implying the electrophoretic mobility shift of AQP5 band can be caused by phosphorylation. These results clearly demonstrated a high specificity of the anti-pAQP5 (T259) antibody developed in the present study. As shown in Fig. 3 , A and C, the anti-pAQP5 (T259) antibody sometimes detected a faint band at a lower position (27.0 kDa), indicating the cross-reactivity with nonphosphorylated AQP5, but it is clear that most clones of this antibody had a high affinity for pAQP5. To eliminate the nonspecific reaction to non-pAQP5 completely, we mixed non-pT259 peptide with the anti-pAQP5 (T259) antibody solution in some of the subsequent experiments.
We also examined the effect of pilocarpine, a muscarinic agonist, on the AQP5 phosphorylated in the salivary glands. In both the SMG and PG, the pAQP5 band was slightly detected in the saline 0-min control, but the intensity of that was not enhanced or seemed to be slightly decreased by the pilocarpine injection (Fig. 5E) .
These results clearly demonstrate that AQP5 was rapidly and transiently phosphorylated upon stimulation by isoproterenol, but not by pilocarpine in the mouse SMG and PG in vivo.
Localization of pAQP5 (T259) in the SMG and PG. Next, we investigated the expression and localization of pAQP5 by immunofluorescence using the anti-pAQP5 (T259) antibody preabsorbed with non-pT259 peptide and fresh-frozen sections of SMG (Fig. 6, A-C) and PG (Fig. 6, D-N) obtained from isoproterenol-injected mice. In either salivary gland of salineinjected mice (0 min), the positive signals for pAQP5 were limited (Fig. 6, A and D) . At 5 min after isoproterenol injection, however, strong immunopositive signals for pAQP5 emerged at the apical membrane and at the membrane of intercellular canaliculi in acinar cells of the SMG and PG (Fig. 6, B and E) . By 60 min, the signals in the acinar cells became markedly weaker (Fig. 6, C and F) . These immunohistochemical results well agree with the results of the pAQP5 time course analysis shown in Fig. 5 . The immunopositive signals that appeared in the PG section by staining with non-preabsorbed anti-pAQP5 (T259) antibody were abolished by preincubation of this antibody with pT259 peptide, but not with non-pT259 peptide (Fig. 6,  G-I) . On the other hand, when the sections of the PG from isoproterenol-injected mice were immunostained with goat anti-AQP5 antibody, the AQP5 was observed as dotlike signals at 0 and 5 min, and as small vacuole-like signals at 60 min in the apical area (Fig. 6, J-L) . Previously, these vacuole-like signals were identified as the part of apical membrane formed during the membrane retrieval after the exocytosis of secretory granules (18) . In the double immunofluorescence, most of pAQP5 signals were present at the same structure that was positive with the anti-AQP5 antibody, indicating that pAQP5 was localized at apical membrane, including intercellular canaliculi in the acinar cells (Fig. 6, K, M, and N) .
Effect of phosphorylation of AQP5 at its Thr259 on its localization in the HSG cells. To investigate the role(s) of phosphorylated AQP5, we first studied the effect of forskolininduced phosphorylation of AQP5 at its Thr259 on the membrane expression of the AQP. That is, HSG AQP5-WT cells were stimulated with forskolin for different times (0 -60 min), followed by biotinylation for analysis of cell-surface proteins. The pAQP5 protein on the cell surface was recovered by absorption and precipitation from streptavidin-agarose. The cell-surface pAQP5 appeared at 2 min after the start of the forskolin treatment, and the level was continuously sustained until 60 min (Fig. 7A, top) . The biotinylated surface AQP5 was detected already in the 0-min control, and this level did not increase at 2 min after the forskolin treatment; in fact, the level remained unchanged until 60 min (Fig. 7A, top) . When the amount of AQP5 among the biotinylated surface proteins was compared between the control and forskolin-treated (for 5 min) cells, no statistical difference (Welch's t-test, P ϭ 0.43, n ϭ 4) was found (Fig. 7B) . Figure 7A (top) showed the pAQP5 and AQP5 changes when these proteins were immunoprecipitated by using anti-AQP5 antibody. The results were essentially the same as those obtained by using streptavidin-agarose precipitation (Fig. 7A, top) . These data indicate that pAQP5, as well as AQP5, at the cell surface did not increase in expression upon forskolin treatment and suggest that stimulation of the cAMP signaling pathway did not affect AQP5 trafficking, although Thr259 of the cell-surface AQP5 was immediately (within 2 min) phosphorylated.
Next, we tried immunofluorescence examination of pAQP5 by using the anti-pAQP5 (T259) antibody to determine its localization; however, this experiment did not detect pAQP5 clearly in HSG AQP5-WT cells for some unknown reason (data not shown). Alternatively, we compared the localization of wild-type AQP5 and its mutant in the HSG cells stably transfected with several AQP5 constructs (AQP5-WT, -T259A, and the same constructs tagged with FLAG) by using anti-AQP5 antibody and anti-FLAG antibody, as shown in Fig. 7C . In the HSG AQP5-WT cells under the unstimulated condition, the signals were observed predominantly in the lateral membrane and in the apical area as spotlike structures, probably in apical microvilli, and slightly in the cytoplasm. Treatment with forskolin for 5 min essentially did not affect the staining pattern of AQP5, suggesting that the AQP5 localization was not altered by forskolin. In HSG AQP5-T259A cell, AQP5 signals were very weak, probably because the antigenicity against anti-AQP5 antibody was decreased (see also Fig. 3A) . We confirmed, however, that the mutant AQP5 in the HSG AQP5-T259A cells existed at apical and lateral membranes similarly, as did the wild-type AQP5 in HSG cells (data not shown). To confirm these results, we stained FLAGAQP5-WT and FLAGAQP5-T259A with anti-FLAG antibody before and after forskolin stimulation, because a stronger signal was expected in this staining experiment, as the anti-FLAG antibody will recognize the epitope remote from Thr259 in the AQP5 molecule. As shown in Fig. 7C , both FLAGAQP5 were clearly observed in lateral membrane and apical area, similar to the localization of AQP5-WT. The immunostaining pattern of either FLAGAQP5-WT or FLA-GAQP5-T259 was essentially the same before and after stimulation by forskolin, again suggesting that AQP5 trafficking was not induced by forskolin in HSG cells.
DISCUSSION
In our present study, we identified a novel phosphorylation site of AQP5, Thr259, and evidently demonstrated that the AQP5 phosphorylation was rapidly induced by PKA through intracellular cAMP signaling, but not through Ca 2ϩ signaling pathways in cultured cells in vitro and in the salivary gland cells in vivo. We found also that AQP5 was constitutively localized in the cell membrane during induction of AQP5 phosphorylation by activation of the cAMP signaling pathway.
To obtain the reliable experimental results for AQP5 phosphorylation, we first needed to optimize a biochemical method regarding effective and mild solubilization of AQP5 for the subsequent specific immunoprecipitation. The differential centrifugation of salivary gland homogenates revealed that AQP5 was effectively recovered in the fraction precipitated at lower speed centrifugation (17,000 g). It was reported that AQP5 is present in lipid rafts (11) , which is a plasma membrane microdomain enriched in cholesterol and sphingolipid and is resistant to nonionic detergent, such as Triton X-100, at a low temperature (12) . Following the examination of various cholesterol-removing detergents, we successfully found and employed the method of sequential treatment with saponin and Triton X-100, as previously reported for solubilization of Thy-1, a glycosyl-phosphatidylinositol-anchored glycoprotein, in mast cells (2) . By virtue of the effective and mild AQP5 solubilization developed in this study, we could specifically immunoprecipitate the AQP5 protein without interfering with the antigen-antibody reactions.
In our analysis of AQP5-WT and AQP5 mutant molecules, with or without the FLAG tag and expressed in HSG cells, we used the indirect pAQP5 detection procedures, i.e., the immunoblot by anti-pPKA substrate antibody after AQP5 immunoprecipitation. This technique clearly demonstrated that AQP5 itself was phosphorylated at its Thr259, but not at other amino acid positions, by PKA through activation of the cAMP signaling pathway. Furthermore, in the direct immunoblotting and immunofluorescence analyses with the use of anti-pAQP5 (T259) antibody, a transient induction of AQP5 phosphorylation was observed in the salivary glands of isoproterenolinjected mice. This result suggests that AQP5 could be phosphorylated at its Thr259 in vivo in fact, and that such process was induced through the cAMP signaling pathway. In our laboratory's previous study, we used AQP5-T259A mutant, tagged with green fluorescent protein at the NH 2 -terminus of AQP5, and concluded that phosphorylation of Thr259 was not necessary for AQP5 trafficking in MDCK cells; however, no experimental evidence of phosphorylation of AQP5 at its Thr259 had been shown (13) . Moreover, no experimental evidence concerning Thr259 of AQP5 as a phosphorylation site has been reported from other groups. Therefore, we concluded that Thr259 of AQP5 is a novel phosphorylation site. Regarding other phosphorylation sites of AQP5, it was previously reported that AQP5 phosphorylation at Ser156 can be induced by PKA through the cAMP signaling in BEAS-2B human bronchial epithelial cells (34) . The difference in AQP5 phosphorylation site between the salivary gland cells and the bronchial cells may be attributed to the difference in their cellular characteristics. At least in salivary gland cells, Thr259 of AQP5 is probably a major phosphorylation site through the cAMP signaling.
Ultrastructural studies of mouse salivary glands have previously shown that AQP5 is localized predominantly in the microvilli of the apical membrane, including the membranes facing the intercellular canaliculi, and slightly in the intracellular vesicles and granules in the acinar cells (5, 18) . In the secretory cycle turned on by isoproterenol stimulation associated with the cAMP signaling pathway, AQP5 does not seem to be endocytosed from the apical membrane, even though membrane retrieval is required after the exocytosis (18) . As found by the salivary gland immunohistochemistry, pAQP5 signals rapidly and transiently appeared at the luminal membrane, but not in the cytoplasm of acinar cells, following stimulation with isoproterenol. Moreover, in HSG cells, both AQP5-WT and AQP5-T259A nonphosphorylated mutant were constitutively localized at the cell membrane, even after the forskolin stimulation. Similar constitutive localization of AQP5 at the plasma membrane was observed in BEAS-2B cells expressing AQP5-WT or AQP5-S156A mutant (34) . Taken together with these several lines of evidence, we suppose that AQP5 is quickly phosphorylated, probably at the plasma membrane rather than in cytoplasmic pools in response to activation of the cAMP signaling pathway. Therefore, AQP5 phosphorylated at its Thr259 does not seem to participate in its membrane targeting or trafficking, such as exocytosis and/or endocytosis, at least in the salivary gland cells, as shown here as a particular example, although cAMP-dependent AQP5 trafficking was reported to occur in MLE-12 cell (26) .
In contrast to the data related to cAMP signaling, AQP5 phosphorylation was not induced or seemed to be slightly decreased through the Ca 2ϩ signaling, as shown by the experimental results of the A23187 treatment in the HSG AQP5-WT cells and of the pilocarpine stimulation in mouse salivary glands. These results imply that AQP5 phosphorylation does not crucially participate in the salivary fluid secretion evoked through the Ca 2ϩ signaling. However, the actual relationship between AQP5 phosphorylation and the Ca 2ϩ signaling is largely unknown at present. It is known that the cAMP and Ca 2ϩ signalings cross talk in the salivary gland cells; e.g., cAMP signaling potentiates the carbachol-elicited Ca 2ϩ response (25, 29) , and M3R stimulation by carbachol can increase or decrease, time and dose dependently, the isoprotere- nol-elicited cAMP accumulation (14, 31) . Thus no increase or a slight decrease of AQP5 phosphorylation through the Ca 2ϩ signaling might be reflected by the intracellular cAMP level under the control of Ca 2ϩ signaling. In conclusion, Thr259, a novel phosphorylation site of AQP5, is potentially phosphorylated through cAMP signaling, but not Ca 2ϩ signaling in the salivary glands. However, the precise physiological role of Thr259-phosphorylated AQP5 is unknown at present. Although the salivary protein secretion in the acinar cells is also a cAMP-mediated event, the direct involvement of this phosphorylation in the protein secretion process is still unclear. Moreover, this phosphorylation does not seem to be predominantly involved in the salivary fluid secretion evoked through the Ca 2ϩ signaling, as described above. On the other hands, our observations also raise a possibility that phosphorylation at Thr259 of AQP5 may regulate the channel gating similar to SoPIP2;1 (30) and mammalian AQP2 (3), because AQP5 seems not to be trafficked through cAMP signaling in the salivary gland cells. Further analyses will be required for better understanding of the physiological role of Thr259-phosphorylated AQP5 in the salivary glands.
